Pfizer Inc. (PFE) Reports Positive Phase 2 Data for 25-Valent Pediatric PCV

Pfizer (PFE) reported Phase 2 results for its 25-valent pneumococcal vaccine, showing immune responses against all 25 serotypes in infants, including five new ones. The vaccine demonstrated higher antibody concentrations against serotype 3 compared to its approved PREVNAR 20 vaccine. Pfizer plans to advance the vaccine into Phase 3 trials and develop a 35-valent vaccine for adults.

Pfizer (PFE) reported Phase 2 data for its 25-valent pneumococcal vaccine candidate, PF-07872412, showing immune responses against all 25 serotypes in infants. The vaccine generated higher immune responses against serotype 3 compared to Prevnar 20. Pfizer is conducting Phase 3 studies and plans to advance a 35-valent vaccine for adults by year-end 2026.

Exploratory analyses of the phase 3 CROWN trial presented at the 2026 ESMO Congress found that baseline and on-treatment ctDNA features, including TP53 mutations, were linked to early progression or prolonged PFS with first-line lorlatinib in ALK-positive NSCLC. Early progressors had more altered genes and TP53 mutations. Undetectable tumor fraction at baseline and its clearance by week 4 were associated with longer PFS.

Pfizer's Phase 2 study of its 25-valent pneumococcal conjugate vaccine candidate (25vPnC) showed robust immune responses in infants, comparable to its PREVNAR 20 vaccine. The candidate includes five new serotypes and uses next-generation technology for serotype 3. Pfizer plans to advance the candidate in Phase 3 trials, aiming to broaden protection against invasive pneumococcal disease in children.

Pfizer's 25-valent pneumococcal vaccine candidate (25vPnC) showed strong immune responses in infants, targeting strains responsible for about 84% of serious pneumococcal disease in U.S. children under 5. The Phase 2 study compared 25vPnC with PREVNAR 20, showing robust responses against 25 serotypes, including five new ones. Pfizer is advancing Phase 3 trials for 25vPnC, aiming to offer broader protection against invasive pneumococcal disease.

Pfizer, Moderna, and others are developing Lyme disease treatments, including vaccines and drugs. Pfizer-Valneva's vaccine showed 73% efficacy in trials, with EU review underway. Tonix and Tarsus are working on preventive measures. Lyme cases have surged, with 476,000 annual diagnoses in the U.S. according to the CDC.